

CODING RESOURCE



1-844-ASK-A360
1-844-275-2360



1-844-FAX-A360
1-844-329-2360



www.MyAccess360.com

For more information, call Access 360™ at 1-844-ASK-A360, Monday through Friday, 8:00 AM to 8:00 PM ET.

Renewed ACIP Recommendation for 2018/2019 Flu Season

The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) recommended that for the 2018-2019 season, immunization providers may choose to administer any licensed, age appropriate influenza vaccine (including Live Attenuated Influenza Vaccine (LAIV), Injectable Influenza Vaccine (IIV), and Recombinant Injectable Vaccine (RIV). LAIV4 is an option for influenza vaccination for persons for whom it is otherwise appropriate.

FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUMIST QUADRIVALENT is for intranasal administration only.

It is important to note that the codes identified below are examples only. Each provider is responsible for ensuring all coding is accurate and documented in the medical record based on the condition of the patient. The use of the following codes does not guarantee reimbursement.

National Drug Code (NDC)

The National Drug Code (NDC) is a universal, unique, 3-segment number identifying drugs by manufacturer, dosage, and package size. Payers may require the submission of the 11-digit NDC on health care claim forms, and electronic claims may be denied for drugs billed without a valid 11-digit NDC. Contact your patient's health plan to determine claim submission requirements and to determine accurate reporting of NDC codes.

10-digit NDC

Dosage	Code
10 applicators in one package	66019-305-10
0.2 mL in one applicator, applicator contained within the package of 10	66019-305-01

11-digit NDC

Dosage	Code
10 applicators in one package	66019-0305-10
0.2 mL in one applicator, applicator contained within the package of 10	66019-0305-01

IMPORTANT SAFETY INFORMATION

- FLUMIST QUADRIVALENT is contraindicated in persons who have had a severe allergic reaction (e.g. anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy
- In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist® (Influenza Vaccine Live, Intranasal)

Please see additional Important Safety Information on adjacent pages and accompanying full Prescribing Information for FLUMIST QUADRIVALENT, including Patient Information.

CODING RESOURCE

Current Procedural Terminology (CPT®)

Submitting accurate codes and claims is important to ensure proper reimbursement of services. The chart below lists the potential Current Procedural Terminology (CPT) code for your reference when submitting claims for your FLUMIST QUADRIVALENT patients.

Code	Description
VACCINE PRODUCT CPT CODE	
90672	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use
PEDIATRIC IMMUNIZATION ADMINISTRATION CPT CODES FOR PATIENTS ≤18 YEARS OF AGE	
90460	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified healthcare professional; first or only component of each vaccine or toxoid administered
90461	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified healthcare professional; each additional vaccine or toxoid component administered (list separately in addition to code for primary procedure)
ADULT IMMUNIZATION ADMINISTRATION CPT CODES FOR PATIENTS >18 YEARS OF AGE	
90473	Immunization administration by intranasal or oral route; one vaccine (single or combination vaccine/toxoid) (Do not use 90473 in conjunction with 90471)
90474	Immunization administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) (Use 90474 in conjunction with 90471 or 90473)

IMPORTANT SAFETY INFORMATION (CONT'D)

- Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FLUMIST QUADRIVALENT administration. FLUMIST QUADRIVALENT has not been studied in persons with severe asthma or active wheezing
- If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST QUADRIVALENT should be based on careful consideration of the potential benefits and risks
- FLUMIST QUADRIVALENT has not been studied in immunocompromised persons

Please see additional Important Safety Information on adjacent pages and accompanying full Prescribing Information for FLUMIST QUADRIVALENT, including Patient Information.

Diagnosis Codes

When filing claims, providers often indicate a diagnosis code reflecting the patient's condition. Based on the Indications for FLUMIST QUADRIVALENT, examples of diagnosis codes that may be appropriate are listed below.

It is important to note that the codes identified below are examples only. Each provider is responsible for ensuring all coding is accurate and documented in the medical record based on the condition of the patient.

The use of the following codes does not guarantee reimbursement.

International Classification of Diseases, Tenth Revision, Clinical Modification = ICD-10-CM

ICD-10-CM	Description
Z23	Encounter for immunization

IMPORTANT SAFETY INFORMATION (CONT'D)

- The safety of FLUMIST QUADRIVALENT in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established
- FLUMIST QUADRIVALENT may not protect all individuals receiving the vaccine
- The most common solicited adverse reactions (occurring $\geq 10\%$ in vaccine recipients and at least 5% greater than in placebo) reported after FLUMIST were runny nose or nasal congestion in all persons 2-49 years, fever $>100^{\circ}\text{F}$ in children 2-6 years, and sore throat in adults 18-49 years. Among children 2-17 years who received FLUMIST QUADRIVALENT, 32% reported runny nose or nasal congestion and 7% reported fever $>100^{\circ}\text{F}$. Among adults 18-49 years who received FLUMIST QUADRIVALENT, 44% reported runny nose or nasal congestion and 19% reported sore throat

INDICATION FOR USE

FLUMIST® QUADRIVALENT is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUMIST QUADRIVALENT is for intranasal administration only.

IMPORTANT SAFETY INFORMATION

- FLUMIST QUADRIVALENT is contraindicated in persons who have had a severe allergic reaction (e.g. anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy
- In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FLUMIST® (Influenza Vaccine Live, Intranasal)
- Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FLUMIST QUADRIVALENT administration. FLUMIST QUADRIVALENT has not been studied in persons with severe asthma or active wheezing
- If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST QUADRIVALENT should be based on careful consideration of the potential benefits and risks
- FLUMIST QUADRIVALENT has not been studied in immunocompromised persons
- The safety of FLUMIST QUADRIVALENT in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established
- FLUMIST QUADRIVALENT may not protect all individuals receiving the vaccine
- The most common solicited adverse reactions (occurring $\geq 10\%$ in vaccine recipients and at least 5% greater than in placebo) reported after FLUMIST were runny nose or nasal congestion in all persons 2-49 years, fever $>100^\circ\text{F}$ in children 2-6 years, and sore throat in adults 18-49 years. Among children 2-17 years who received FLUMIST QUADRIVALENT, 32% reported runny nose or nasal congestion and 7% reported fever $>100^\circ\text{F}$. Among adults 18-49 years who received FLUMIST QUADRIVALENT, 44% reported runny nose or nasal congestion and 19% reported sore throat

Please see accompanying full Prescribing Information for FLUMIST QUADRIVALENT, including Patient Information.

You are encouraged to report negative side effects of AstraZeneca prescription drugs by calling 1-800-236-9933. If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.



FluMist® Quadrivalent
Influenza Vaccine Live, Intranasal

FLUMIST is a registered trademark of the AstraZeneca group of companies.
CPT is a registered trademark of the American Medical Association.
©2018 AstraZeneca. Gaithersburg, MD 20878. All rights reserved. US-19181 8/18
1-877-FLUMIST (358-6478) www.FluMistQuadrivalent.com

AstraZeneca